Journal of Immunotherapy and Precision Oncology最新文献

{"title":"Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA.","authors":"","doi":"10.36401/JIPO-26-X1","DOIUrl":"10.36401/JIPO-26-X1","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 2","pages":"32-35"},"PeriodicalIF":3.1,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies.","authors":"Umut Dişel, Shumei Kato, Aditya Shreenivas, Ayca Ersen Danyeli, Manmeet S Ahluwalia, Razelle Kurzrock","doi":"10.36401/JIPO-25-34","DOIUrl":"10.36401/JIPO-25-34","url":null,"abstract":"<p><strong>Background: </strong>High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14-16 months in patients with glioblastoma (GBM).</p><p><strong>Methods: </strong>We report four patients with high-grade glioma (two with GBM; one initially diagnosed with GBM, now classified as World Health Organization grade 4 <i>IDH1-</i>mutant astrocytoma; and one with oligosarcoma [grade 4]). Tumor next-generation sequencing (NGS) was performed for all four patients, and they were treated based on their biomarkers.</p><p><strong>Results: </strong>NGS yielded actionable alterations targeted after conventional surgery/chemoradiation therapy: imatinib (for <i>KIT</i> and <i>PDGRA</i> amplification) and bevacizumab (for <i>KDR</i> [<i>VEGFR2</i>] amplification); everolimus (mTOR inhibitor for <i>TSC2</i> and <i>PTEN</i> loss-of-function alterations); and ivosidenib (IDH1 inhibitor for <i>IDH1</i> mutations in two cases, including the oligosarcoma). Three patients remain in radiographic and clinical remission at 39+, 48, and 52+ months; the patient with oligosarcoma showed clinical and imaging response lasting 8 months.</p><p><strong>Conclusions: </strong>Our exceptional responders with high-grade gliomas suggest that biomarker-matched targeted therapy can benefit select patients with high-grade glioma and warrants prospective clinical trials.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 1","pages":"25-31"},"PeriodicalIF":3.1,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced <i>KRAS</i>-Mutated Metastatic Pancreatic Cancer.","authors":"Muhammad Rizwan Khawaja, Gayle Jameson, Derek Cridebring, Patricia Shannon, Haiyong Han, Jaeger Moore, Daniel Von Hoff, Richard G Posner, William S Hlavacek, Walter Kolch, Boris N Kholodenko, Oleksii S Rukhlenko, Denise J Roe, Betsy C Wertheim, Erkut Borazanci","doi":"10.36401/JIPO-25-20","DOIUrl":"10.36401/JIPO-25-20","url":null,"abstract":"<p><strong>Introduction: </strong>Prognosis of metastatic pancreatic cancer remains poor. <i>KRAS</i> mutations are common in pancreatic cancer and are an attractive therapeutic target. Based on a next-generation mechanistic dynamic model, we hypothesized that a combination of type I½ RAF inhibitor (vemurafenib) and type II RAF inhibitor (sorafenib) would have clinical activity in <i>KRAS</i>-mutated advanced pancreatic cancer.</p><p><strong>Methods: </strong>We conducted an open-label pilot phase II trial of vemurafenib and sorafenib combination in advanced pancreatic cancer with <i>KRAS</i> mutations. Eligible patients had progressed on two or more prior treatment regimens, had adequate performance status, adequate organ function and measurable disease, and were able to swallow oral medication. The primary objective was disease control rate (partial or complete response or stable disease ≥ 16 weeks). Secondary objectives included safety, progression-free (PFS) and overall survival (OS), and changes in plasma phospho-ERK and phospho-AKT.</p><p><strong>Results: </strong>Nine patients with <i>KRAS-</i>mutated pancreatic cancer were enrolled. The median age was 62.8 years and the median prior lines of treatment was 3. Four of the initial five patients had treatment interruption due to adverse events, and the subsequent four patients were treated at a reduced dose. Three grade 3 adverse events were reported and included anemia (<i>n</i> = 1), hypophosphatemia (<i>n</i> = 1), and maculopapular rash (<i>n</i> = 1); rash and anemia were deemed treatment related. Disease control rate was 0%. Median PFS was 1.6 months (95% CI, 0.5-not available), and median OS was 2.9 months (95% CI, 0.6-5.4). Compared to baseline, the best response for relative plasma phospho-ERK levels were -39 to +11% and -32 to +49% for plasma phospho-AKT levels.</p><p><strong>Conclusion: </strong>The combination of vemurafenib and sorafenib in <i>KRAS</i>-mutated refractory pancreatic cancer did not yield disease control in this pilot phase II study. The lack of clinical efficacy may be due to inadequate inhibition of RAS-to-ERK signaling as toxicities necessitated dose reduction.</p><p><strong>Clinicaltrialsgov id: </strong><b>NCT05068752</b>.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 1","pages":"17-24"},"PeriodicalIF":3.1,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.","authors":"Lee S Rosen, Christian Ottensmeier, Maria Hawkins, Aung Naing, Guru Sonpavde, Brian A Van Tine, Eileen E Parkes, Sean M O'Cathail, Rui-Ru Ji, Matthew Thomas, Andrea Stacey, Maria Stella Sasso, Oliver Rosen","doi":"10.36401/JIPO-25-18","DOIUrl":"10.36401/JIPO-25-18","url":null,"abstract":"<p><strong>Introduction: </strong>Enadenotucirev (EnAd) and successor transgene-armed Tumor-Specific Immuno-Gene (T-SIGn) vectors are replication-competent, blood-stable viral vectors that traffic to tumor sites following intravenous (IV) administration. Following initial proof of mechanism for this immunotherapy modality, there is a need to identify a safe dosing approach, understand whether transgenes affect tolerability, and determine how to measure exposure and pharmacodynamic effects.</p><p><strong>Methods: </strong>Safety data from multiple phase 1 trials were aggregated to assess various dosing regimens and toxicities, including those that may be associated with transgene arming. Viral delivery to tumors, peripheral viral persistence, transgene expression, and cytokine responses were also assessed and compared between the unarmed EnAd and armed T-SIGn vectors.</p><p><strong>Results: </strong>IV administration of EnAd and the armed T-SIGn vectors led to virus detection in epithelial tumors and prolonged peripheral virus persistence. Despite the short half-life of the viruses and cell-free nucleic acids, viral DNA or transgene messenger RNA (mRNA) remained detectable in blood at higher dose levels for at least 56 days, indicating sustained release of these molecules likely driven by ongoing viral replication and concomitant transcription of the transgene in tumors. Safety, predominantly defined by the effects of IV administration and associated viremia, was managed by a well-tolerated dosing regimen. To date, no transgene-related or off-target toxicities have been observed. Transient monocyte chemoattractant protein 1 (MCP-1) and interleukin (IL)-6 elevations were associated with viremia. A second phase of elevations of proinflammatory cytokines such as IL-12p70, interferon (IFN) α2, IL-17A, and IFNγ without clinical symptoms started around day 12, suggesting that release of these cytokines was driven by localized pharmacodynamic effects within the tumor microenvironment (TME).</p><p><strong>Conclusion: </strong>Armed T-SIGn vectors exhibit the same high tumor selectivity and replicative activity as the unarmed parent EnAd and achieve consistent viral delivery to a broad range of epithelial tumor tissues. The aggregated safety analysis revealed that safety and tolerability are defined by systemic viremia but not off-target or transgene-related toxicities. Nucleic acid and cytokine release from tumors and changes in the TME (e.g., CD8+ T cells), indicative of the mechanism of action of replication-competent viral vectors, constitute potentially valuable data to support the definition of a recommended phase 2 dose and the assessment of the benefit of multicycle administration.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 4","pages":"263-275"},"PeriodicalIF":3.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12681188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.","authors":"Khanh Toan Nguyen, Thi Huong Pham, Van Lam Ngo, Thi Thuy My Nguyen, Thi Dao Nguyen, Van Thanh Le, Van Nhat Nguyen, Thi Thanh Thuy Nguyen, Khanh Ha Nguyen, Thi Nhung Ngo, Thi Hai Yen Le, Thi Phuong Thao Nguyen, Thi Ha Phuong Nguyen, Thi Hong Anh Vo, Thi Thuy Phan, Khanh Hung Truong, Ba Duc Ho, Thi My Linh Dinh","doi":"10.36401/JIPO-25-12","DOIUrl":"10.36401/JIPO-25-12","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to document patient characteristics, treatment modalities, and survival outcomes of patients with lung cancer in Vietnam from 2018 to 2024.</p><p><strong>Methods: </strong>This was a retrospective study of patients with lung cancer treated at Nghe An Oncology Hospital over a 6-year period (2018-2024). The primary endpoints included lung cancer treatment methods for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and overall survival (OS). Secondary endpoints involved factors related to survival duration.</p><p><strong>Results: </strong>A total of 3548 patients were included: 3087 with NSCLC (87%) and 419 with SCLC (11.8%) (median age 64 years, range 18-97 years; 3:1 male-to-female ratio). Adenocarcinoma (AC) was the predominant histologic subtype (67%), followed by squamous cell carcinoma (SCC) (13.4%). <i>EGFR</i> mutation was detected in 43.2% of cases. From 2018 to 2024, the proportion of early-stage lung cancer diagnoses (stages I and II) increased from 2.7% to 9%, and the detection rate of advanced or metastatic stages (stages III and IV) decreased. Surgery was the primary treatment for localized NSCLC (62.5%), and stage III cases predominantly received radiation and chemotherapy (40.8%), including 38.6% with concurrent chemoradiotherapy. In stage IV NSCLC, chemotherapy was the most common treatment (53.9%), followed by targeted therapy (25.2%) and immunotherapy (1.9%). SCLC was mostly diagnosed at the extensive stage (68.0%), with chemotherapy being the mainstay of treatment (73.0%), followed by chemoradiotherapy (12.9%) and palliative care (13.1%). Median OS was 15.3 months (95% CI, 14.5-16.1), with a 5-year survival rate of 14.2%. Median OS for NSCLC cases was 16.4 months (95% CI, 15.4-17.4), with 5-year survival rates of 55.2%, 47.6%, 20.2%, and 8.3% for stages I, II, III, and IV, respectively. Median OS for SCLC cases was 11.0 months (95% CI, 9.7-12.4), with a 5-year survival rate of 4.7%. Independent prognostic factors for mortality included male sex, poor performance status (PS ≥ 2), small cell histology, metastatic disease, brain metastases, and initial nonsurgical treatment.</p><p><strong>Conclusion: </strong>This study provides critical data on the epidemiology and prognosis of lung cancer in Vietnam, highlighting the role of personalized treatment approaches in improving clinical outcomes. These findings underscore the urgent need for integrated public health strategies to enhance early detection and access to advanced therapies, thereby reducing the lung cancer burden in Vietnam.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 4","pages":"254-262"},"PeriodicalIF":3.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12681187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.","authors":"AbdulAziz AlJassim, Aladdin Kanbour, Fathi Azribi, Muath AlNassar, Riadh Mohsen, Sahar Dawod, Selvaraj Giri, Michael Nasr Kamal, Ali AlJabban, Layth Mula-Hussain, Bader Alshamsan, Emad Anwar","doi":"10.36401/JIPO-24-35","DOIUrl":"10.36401/JIPO-24-35","url":null,"abstract":"<p><p>Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of <i>ALK</i>, <i>EGFR</i>, <i>KRAS</i>, <i>ROS1</i>, <i>MET</i>, <i>BRAF</i>, and <i>HER2</i> mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region. The systematic literature review was performed using PubMed, Google Scholar, and Google searches to identify studies on the prevalence of <i>ALK</i>, <i>EGFR</i>, <i>KRAS</i>, <i>ROS1</i>, <i>MET</i>, <i>BRAF</i>, and <i>HER2</i> mutations in patients with NSCLC in the MENA region. Additionally, 10 experts from the GCC region were interviewed to provide insights into molecular mutation testing, the challenges faced, and the current approaches to targeted therapies. The prevalence of <i>ALK</i>, <i>EGFR</i>, <i>KRAS</i>, <i>ROS1</i>, <i>MET</i>, and <i>BRAF</i> mutations was 7.9% (95% CI, 6.69-9.03%), 24% (95% CI, 22.05-25.41%), 19.7% (95% CI, 15.29-24.07%), 2.2% (95% CI, 0.77-3.57%), 4.7% (95% CI, 2.29-7.07%) and 3.7% (95% CI, 1.54-5.80%), respectively. <i>HER2</i> mutation data were unavailable. Treatment generally adhered to international guidelines, with therapy selection based on tumor stage, molecular profile, and drug availability. Expert opinions highlighted significant advancements in molecular diagnostics and targeted therapies but also pointed out the challenges in standardizing and implementing these techniques across the GCC region. This review underscores the importance of personalized and region-specific approaches to NSCLC treatment, given the significant differences in mutation patterns in the MENA region. Further research is needed to gain a more comprehensive understanding of the prevalence and effect of driver mutations across broader MENA countries to inform future treatment strategies.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 3","pages":"233-241"},"PeriodicalIF":3.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.","authors":"Sammy Shaya, Okezie Uche-Ikonne, Bedirhan Kilerci, Julie Stevenson, Alastair Greystoke, Natalie Cook, Fiona C Thistlethwaite, Louise Carter, Donna M Graham, Matthew G Krebs","doi":"10.36401/JIPO-25-11","DOIUrl":"10.36401/JIPO-25-11","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clinical benefit and meet trial endpoints with fewer participants. One in six participants does not meet routine life expectancy requirements (>3 months), highlighting the need for improved prognostication. Variant allele frequency (VAF) in circulating tumor DNA (ctDNA) correlates with overall survival (OS) in advanced solid tumors. We aimed to derive an optimal VAF threshold as a prognostic biomarker to enhance participant selection.</p><p><strong>Methods: </strong>ctDNA testing was performed as part of the TARGET (NIHR Clinical Research Network CPMS ID 39172) and TARGET National (NCT04723316) prospective cohort studies, in patients with advanced solid tumors referred for early phase clinical trials. Maximum (maxVAF) and mean VAF (meanVAF) were compared in their association with OS and ability to delineate favorable and poor outcomes at set threshold points using hazard ratios (HRs). Optimal thresholds of VAF were explored using receiver operating characteristic curve analysis to predict 3-month landmark OS. Univariable and multivariable analysis was performed to determine whether VAF was an independent prognostic marker.</p><p><strong>Results: </strong>Of 631 patients, 587 had evaluable ctDNA results. MeanVAF and maxVAF exhibited similar correlation with OS (r_s = -0.32 vs -0.35, respectively) and similar prognostic utility at matched threshold points. A maxVAF value of 4% was selected as optimal for prognostic subgrouping (area under curve 0.77). OS was 5.9 versus 12.1 months (<i>p</i> < 0.0001) for patients with more than 4% and 4% or less maxVAF, respectively. Multivariable analysis confirmed more than 4% maxVAF as independently associated with reduced 3-month landmark OS (HR 2.17 [1.76-2.70], <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>VAF is an independent prognostic marker in patients with advanced solid tumors, with 4% maxVAF deemed optimal for delineating favorable and poorer prognostic subgroups in this patient cohort. Further validation and integration into existing prognostic scores are warranted.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 3","pages":"222-232"},"PeriodicalIF":3.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment.","authors":"Aleksandra Watson, Gina D'Amato, Emily Jonczak, Steven Bialick, Jonathan Trent","doi":"10.36401/JIPO-25-10","DOIUrl":"10.36401/JIPO-25-10","url":null,"abstract":"<p><p>The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors with immune checkpoint inhibitors (ICIs) in sarcoma. It is difficult to draw conclusions owing to limited data and primarily single-arm studies, although initial literature appears promising and requires further study. It remains unknown which sarcoma subtypes may derive the most benefit owing to the limited literature. Benefit was seen primarily in angiosarcoma (AS) and alveolar soft part sarcoma (ASPS), as well as in other tumor subtypes, with few patients achieving complete response (CR). The patients who achieved CRs had desmoplastic small round cell tumor (DSRCT), AS, and chondrosarcoma (CS). Mixed results were found in patients with leiomyosarcoma (LMS), gastrointestinal stromal tumor (GIST), and bone sarcomas, although combination therapy appears to be less effective in these subtypes. Further studies are required to explore optimal treatment agents and dosing strategies to improve both efficacy and tolerability. Although initial results are promising in select patients, phase 3 randomized controlled trials are necessary to determine true treatment effect with combination therapy versus VEGF-inhibitor or ICI alone.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 3","pages":"212-221"},"PeriodicalIF":3.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional Response to Immunotherapy-based Treatment in Compound <i>EGFR</i>-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report.","authors":"Ayushi Gianchandani, Darshana Desai, Janani Sambath, Darshana Patil, Prashant Kumar, Shambhavi Singh, Chetan Madre, Ruturaj Deshpande, Anjali Parab, Niyati Shah, Darshit Shah, Pritam Kataria, Shrikanth Atluri, Marzi Mehta, Aditya Shreenivas, Rajan Datar, Razelle Kurzrock, Sewanti Limaye","doi":"10.36401/JIPO-25-7","DOIUrl":"10.36401/JIPO-25-7","url":null,"abstract":"<p><p>Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. <i>EGFR</i> mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound <i>EGFR</i> mutations (p.G719C and S768I). The patient exhibited disease progression despite sequential treatment with EGFR TKIs, including osimertinib, afatinib, and mobocertinib, in combination with chemotherapy. The treatment strategy was then shifted to immunotherapy with pembrolizumab alongside carboplatin and paclitaxel, leading to a remarkable response. Given the oligometastatic nature of the disease and the sustained response, bilateral adrenalectomy was performed, revealing a complete pathological response. The patient remains disease-free posttreatment, with no evidence of recurrence on follow-up imaging. This case challenges the conventional paradigm that <i>EGFR</i>-mutated NSCLC does not benefit from immunotherapy, highlighting the potential for an alternative treatment approach in rare subtypes such as PSC. Our findings emphasize the importance of comprehensive molecular profiling and a personalized treatment strategy to optimize outcomes in aggressive and refractory lung cancers.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 3","pages":"206-211"},"PeriodicalIF":3.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts Presented at the 2024 Emirates Oncology Conference: November 15-17, 2024, Abu Dhabi, United Arab Emirates.","authors":"","doi":"10.36401/JIPO-25-X4","DOIUrl":"https://doi.org/10.36401/JIPO-25-X4","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 3","pages":"194-205"},"PeriodicalIF":3.2,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}